backOn March 6, 2026, the Food and Drug Administration (“FDA” or “the Agency”) issued a draft guidance, “Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection.”1See FDA, Guidance for Industry (draft), Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection (Mar. 2026), https://www.fda.gov/regulatory-information/search-fda-guidance-documents/responding-fda-form-483-observations-conclusion-drug-cgmp-inspection. The draft guidance articulates detailed expectations for the content, timing, and quality of FDA 483 responses for drug inspections, the role of management and quality systems, and the handling of scientific or technical disagreements.
The draft guidance applies to foreign and domestic human and animal drug manufacturing establishments whose products are regulated by the Center for Drug Evaluation and Research (“CDER”), the Center for Biologics Evaluation and Research (“CBER”), or the Center for Veterinary Medicine (“CVM”), as well as combination product manufacturers where CDER or CBER is the lead center.2See id. at 1. Its purpose is to recommend a standardized format and content for responses; describe expectations for investigation, risk assessment, and corrective and preventive action (“CAPA”) plans; clarify management's responsibilities; and provide an approach for resolving scientific or technical disagreements. The guidance does not create new legal obligations; manufacturers remain independently responsible for operating in compliance with current good manufacturing practices (“cGMPs”). 3See id. at 2.
The FDA Form 483
At the conclusion of an inspection, FDA investigators typically issue an FDA 483 when, in their judgment, they have observed objectionable conditions that may constitute violations of the Federal Food, Drug, and Cosmetic Act (“FD&C Act”) or FDA regulations. The FDA 483 lists inspectional observations but does not represent FDA’s final findings or conclusions regarding compliance with applicable requirements. 4See id. Although responding to inspectional observations is technically voluntary, in King & Spalding’s experience, the failure to respond to an FDA 483 risks a Warning Letter or a Complete Response Letter. In fact, FDA states in the Draft Guidance that the response “may be the primary or a key component” in FDA’s evaluation of whether to take subsequent action, and the Agency recommends that establishments submit written responses.5Id. at 3. A response allows establishments to explain potential product quality impact, outline remediation plans, and provide context on scope and systemic issues.
FDA 483 Response Format, Content, and Timing
Response Format and Content
Not surprisingly, FDA recommends that FDA 483 responses be accurate, clear, concise, and well-organized. The Agency prefers a single, comprehensive response addressing all observations rather than multiple response submissions to individual observations.6See id. at 6. For the first time, FDA describes the format that it recommends the response take. Some aspects of this FDA-preferred format may be different from the approach that many drug and biologics manufacturers currently follow. FDA recommends that the response include a table of contents and also contain the identity of the establishment submitting the response in addition to the inspected site’s identifying information such as the FDA Establishment Identifier (“FEI”) number.7See id. at 4. If the response is prepared with the assistance of consultants or outside counsel, it should include the identity of such outside advisers, an explanation of their role in preparing the response, and any related letters of authorization; presumably, such letters are required only if the consultants or outside counsel are submitting the response on the firm’s behalf. FDA recommends that the signatory of the response be a member of the establishment’s executive management with the authority to implement the commitments made in the response.8See id.
FDA 483 responses should show that an establishment has addressed or is actively addressing the observations identified by the inspection, and the underlying causes of those observations.9See id. at 3. To do so, the response should include an executive summary, potentially in table format, of all remediation activities, followed by a more detailed description of each observation or cluster of observations as well as associated remedial measures. It should contain a patient and product-focused risk assessment evaluating any possible effects of the observations on the safety, identity, strength, quality, and purity of any potentially affected drugs. It should also include a detailed investigation report including an explanation of the scope of the investigation, identified root cause(s) of the observations, a CAPA plan, a summary of completed actions, and a description of a planned effectiveness evaluation (with results, if available).10See id. at 4.
Establishments should include attachments with objective evidence related to the associated observations. In a surprising suggestion, FDA recommends that each attached document be individually signed, indicating the firm’s support for their contents.11See id. at 5. This is not a response practice common in industry’s current approach to FDA 483 responses.
Response Timing and Interim Reporting
FDA recommends that establishments respond within 15 business days after the issuance of the FDA 483, or, if the FDA 483 was amended, within 15 business days after the amendment.12See id. at 6 In King & Spalding’s experience, when calculating the 15-business day timeline, the day FDA issues the FDA 483 is day 0, and is not part of the 15-business day timeline. Furthermore, business days exclude U.S. federal holidays defined in 5 U.S.C. § 6103. Timely responses will generally receive a “detailed review” before the Agency decides on further action.13Id. FDA cautions that it will “not ordinarily delay” regulatory action to review responses submitted later than the 15-business-day window.14Id. For complex issues, establishments should at least submit a CAPA plan and proposed timeframe for substantive follow-up within the 15-day window. 15See id. at 5.
Recommendations for Addressing Observations
Assessing Observations and Management’s Role
The draft guidance emphasizes quality risk management. Firms should assess observations for the level of risk presented and prioritize taking timely and appropriate action on that basis. In doing so, an establishment may choose to cluster observations into general categories (e.g., investigations, cleanrooms, staff competencies) or by system (e.g., quality, production, packaging and labeling). The establishment should seek to identify repeat observations or trends by comparing observations with internal audits and past inspections, including inspections at other facilities within the organization.16See id. at 7. FDA expects that a holistic approach will be applied to addressing observations and that corrective actions will be extended globally across the company’s network.
FDA expects that management will play a central role in responding to an FDA 483. An establishment’s management should review the FDA 483 at the facility level and, if applicable, at the corporate level. Management should ensure that adequate resources are dedicated to investigation and remediation and if interim CAPAs are needed to address urgent risks. Management should form a “multidisciplinary investigation team” to conduct an objective and effective investigation and this team “should have full support, including regular communication, from executive management.”17Id. at 8-9.
Investigation and CAPA Plans
FDA recommends a written investigation plan with a risk-based, scientifically justified scope and methodology. For finished drugs, investigations must be consistent with 21 C.F.R. § 211.192, including thorough investigation of discrepancies and specification failures, assessment of affected batches, and documented conclusions.18See id. at 9. Investigations should include a risk assessment, structured root-cause analysis (recognizing that multiple root causes may exist), and consideration of why issues were not previously identified. Investigations should expand in scope as necessary.19See id. at 10.
CAPA planning should begin during or immediately after the inspection and should be updated as the investigation progresses. A CAPA plan should describe remedial measures that address the root cause or causes identified by the investigation. The remedial measures should be commensurate with the level of risk identified by the investigation’s risk assessment. The CAPA plan should include a communication plan with clear steps toward completion, timeliness, and deliverables. 20See id. at 11.
FDA views CAPA effectiveness checks as fundamental; establishments should use a monitoring system to track overall CAPA effectiveness and, if assessments indicate inadequacy, establishments should revisit both the investigation and the CAPA plan. The guidance clarifies that routine sampling and testing is not sufficient.21See id.
Scientific or Technical Disagreements
The draft guidance acknowledges that scientific or technical disagreements may arise during inspections. Establishments should seek clarification with FDA representatives during the inspection. If a significant disagreement remains unresolved when an FDA 483 is issued, the written response should clearly describe contested facts and provide supporting scientific data and supporting information, including references to applicable statutes, regulations, and guidance. Remember, the observations on the FDA 483 are based on the investigator’s judgement. 22See id. at 13. Additional recourse includes contacting the FDA Ombudsman 23See id. at 12. requesting a Type A meeting with FDA management.
Takeaways
When finalized, the draft guidance will formalize FDA’s expectations for responding to FDA 483s. Important elements of the draft guidance include FDA’s calling for executive-level engagement and cross-functional investigation teams and stressing rigorous product- and patient-focused risk assessments and documented CAPAs with effectiveness checks. Manufacturers should evaluate their inspection response procedures, investigation practices, and CAPA systems against the draft guidance and consider enhancements to align with FDA’s expectations.
FDA’s proposed response format , with an executive summary (potentially in tabular format), preceding a more detailed observation-by-observation format, may be unfamiliar for some manufacturers, as may be FDA’s recommendation that all response attachments be signed by the firm. These format recommendations likely will prove to be less important than FDA’s substantive recommendations for developing a robust and comprehensive approach to addressing the observations and their root causes. However, when the draft guidance is finalized with the format recommendations, manufacturers should seriously consider implementing the Agency’s formatting guidance; if the Agency recommended approach becomes the industry norm, then it will be more comfortable reviewing responses that take the recommended approach.
Comments on the draft guidance may be submitted to the designated FDA docket, FDA-2025-D-1504, through May 6, 2026.